Literature DB >> 215096

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

D R Jasinski, J S Pevnick, J D Griffith.   

Abstract

Buprenorphine was evaluated for its abuse potential and utility in treating narcotic addiction. The drug was morphine-like but was 25 to 50 times more potent than morphine and was longer-acting. Little if any physical dependence of clinical significance was produced by buprenorphine. The effects of morphine to 120-mg doses were blocked by buprenorphine, a blockade that persisted for 29 1/2 hours. In man, buprenorphine has less intrinsic activity than morphine, and as such, as a low abuse potential. Moreover, the drug has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 215096     DOI: 10.1001/archpsyc.1978.01770280111012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  142 in total

Review 1.  The medical management of adolescent heroin dependence.

Authors:  A B Rowan; P J Fudala; J Mulligan
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 2.  Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

3.  Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Authors:  E C Strain; J A Harrison; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

4.  Managing opioid dependence. Comparing buprenorphine with methadone.

Authors:  Chris Cavacuiti; Peter Selby
Journal:  Can Fam Physician       Date:  2003-07       Impact factor: 3.275

5.  Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs.

Authors:  M J Rance
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

6.  Analgesic effectiveness of the narcotic agonist-antagonists.

Authors:  R W Houde
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

8.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

9.  Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.

Authors:  H Fukase; K Fukuzaki; T Koja; R Nagata; S E Lukas
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

10.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.